EGFR and non-small cell lung carcinoma: Taken together, our results suggest that, although the mutation-dependent mechanism would be complex, the depletion of both miR-200c and miR155 by chronic treatment of NSCLC cells with gefitinib may act as a trigger for the EMT and contribute to gefitinib-resistance independent of a secondary T790M mutation in EGFR.